ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $34,908.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $87.27, for a total value of $34,908.00. Following the sale, the vice president directly owned 75,274 shares in the company, valued at approximately $6,569,161.98. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Monday, October 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $90.09, for a total transaction of $36,036.00.
• On Friday, September 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $98.42, for a total transaction of $39,368.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded down $0.53 during trading on Friday, hitting $84.02. 394,304 shares of the company traded hands, compared to its average volume of 370,722. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -109.12 and a beta of 0.54. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The business’s fifty day moving average is $92.99 and its 200-day moving average is $78.04.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period last year, the business posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on ANIP shares. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Piper Sandler reissued an “overweight” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright upped their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $99.29.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its stake in ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after acquiring an additional 400 shares in the last quarter. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.